Non-Hodgkin Lymphoma
Show Only Open Trials
1.
Gilead 0125: A Study Evaluating the Efficacy and Safety of Idelalisib(GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Previously Treated Indolent non-Hodgkin Lymphoma
- Protocol ID: Gilead 0125
2.
Gilead 0124: A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Previously Treated Indolent non-Hodgkin Lymphoma
- Protocol ID: Gilead 0124
3.
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas: the ARROVEN study
- Study Status: Open to Enrollment
- Sponsor: Seattle Genetics
- Disease Status and/or Stage: Untreated Mature T-Cell Lymphoma
4.
A051103: A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Alliance for Clinical Trials in Oncology
- Disease Status and/or Stage: Untreated Follicular Lymphoma
- Protocol ID: A051103
5.
Alliance A051202: A Phase I Trial of Lenalidomide, Rituximab, and Idelalisib in Recurrent Follicular Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Alliance for Clinical Trials in Oncology
- Disease Status and/or Stage: Recurrent Follicular non-Hodgkin Lymphoma
- Protocol ID: A051202
6.
A Phase Ib/IIa Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma
- Study Status: Open to Enrollment
- Sponsor: Memorial Sloan-Kettering Cancer Center
- Disease Status and/or Stage: Relapsed or Refractory Lymphoma and Multiple Myeloma
7.
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects with Relapsed or Refractory Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Janssen and Pharmacyclics
- Disease Status and/or Stage: Relapsed or Refractory Mantle Cell Lymphoma
- Protocol ID: PCI-32765MCL4001
8.
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies
- Study Status: Open to Enrollment
- Sponsor: OncoMed
- Disease Status and/or Stage: Relapsed or Refractory Lymphoid Malignancies, Including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Transformed Mycosis Fungoides (MF), or Sezary Syndrome
- Protocol ID: 52M51-001
9.
An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Janssen
- Disease Status and/or Stage: Refractory Follicular Lymphoma
- Protocol ID: PCI-32765FLR2002
10.
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy
- Study Status: Open to Enrollment
- Sponsor: Allos Therapeutics
- Disease Status and/or Stage: Peripheral T-Cell Lymphoma
- Protocol ID: PDX-017
11.
A Multicenter Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated with Rituximab and Vincristine
- Study Status: Open to Enrollment
- Sponsor: Millennium
- Disease Status and/or Stage: Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma or Burkitt Lymphoma
- Protocol ID: C14011
12.
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Millennium
- Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell Lymphoma
- Protocol ID: C14012
13.
A Randomized study of Combined Haplo-identical Umbilical Cord Transplantation vs. Double Umbilical Cord Transplantation in Patients with Hematologic Malignancies
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
14.
BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
- Study Status: Open to Enrollment
- Sponsor: BMT-CTN
- Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
- Protocol ID: BMT CTN 0903
15.
CALGB 50901: A Phase II Trial of Ofatumumab (CALGB IND #112390) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Untreated Follicular Lymphoma
- Protocol ID: CALGB 50901
16.
S1108: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
- Study Status: Open to Enrollment
- Sponsor: SWOG
- Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell non-Hodgkin Lymphoma
17.
Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
18.
CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Untreated Follicular Lymphoma
- Protocol ID: CALGB 50904
19.
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo diffuse Large B-Cell Lymphoma (PCYC 1106)
- Study Status: Open to Enrollment
- Sponsor: Pharmacyclics
- Disease Status and/or Stage: Relapsed or Refractory de Novo Diffuse Large B-cell Lymphoma (DLBCL)
20.
Phase II Study of Lenalidomide plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Untreated Mantle Cell Lymphoma
21.
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
- Study Status: Open to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Previously untreated Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
22.
Phase 1 Study of PD 0332991 Plus Bortezomib in Patients with Previously Treated Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
